US Bancorp
AKBA icon

US Bancorp’s Akebia Therapeutics AKBA Stock Holding History

US Bancorp’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,121
Closed -$58.7K – 4005
2025
Q2 		$58.7K Sell
16,121
-1,584
-9% -$4.35K ﹤0.01% 2700
2025
Q1 		$34K Buy
17,705
+81
+0.5% +$165 ﹤0.01% 2934
2024
Q4 		$33.5K Hold
17,624
– – ﹤0.01% 2929
2024
Q3 		$23.3K Buy
+17,624
New +$23.5K ﹤0.01% 3069
2021
Q3 		– Sell
-309
Closed -$1K – 4062
2021
Q2 		$1K Hold
309
– – ﹤0.01% 3882
2021
Q1 		$1K Sell
309
-1,691
-85% -$6.09K ﹤0.01% 3762
2020
Q4 		$6K Hold
2,000
– – ﹤0.01% 3329
2020
Q3 		$5K Hold
2,000
– – ﹤0.01% 3275
2020
Q2 		$27K Hold
2,000
– – ﹤0.01% 2674
2020
Q1 		$15K Hold
2,000
– – ﹤0.01% 2869
2019
Q4 		$13K Hold
2,000
– – ﹤0.01% 3023
2019
Q3 		$8K Hold
2,000
– – ﹤0.01% 3114
2019
Q2 		$10K Hold
2,000
– – ﹤0.01% 3084
2019
Q1 		$16K Sell
2,000
-8,253
-80% -$56.6K ﹤0.01% 2929
2018
Q4 		$57K Hold
10,253
– – ﹤0.01% 2380
2018
Q3 		$91K Buy
10,253
+4,139
+68% +$37K ﹤0.01% 2267
2018
Q2 		$61K Hold
6,114
– – ﹤0.01% 2470
2018
Q1 		$58K Sell
6,114
-1,486
-20% -$20.8K ﹤0.01% 2513
2017
Q4 		$113K Buy
7,600
+1,486
+24% +$24.6K ﹤0.01% 2188
2017
Q3 		$120K Buy
6,114
+5,114
+511% +$78.6K ﹤0.01% 2134
2017
Q2 		$14K Buy
+1,000
New +$12.7K ﹤0.01% 2985

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

US Bancorp's AKBA Position: Q3 2025 in Review

US Bancorp sold out of Akebia Therapeutics (AKBA) in Q3 2025, closing a stake of 16,121 shares — an estimated $58.7K sold.

US Bancorp first reported a position in AKBA in Q2 2017 and held it in 21 quarters. The position peaked at $120K in Q3 2017. 177 funds tracked by Wall St. Rank hold AKBA as of Q3 2025.

  • US Bancorp reported no remaining Akebia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • US Bancorp sold 16,121 Akebia Therapeutics shares in Q3 2025, an estimated $58.7K.
  • US Bancorp first reported a position in Akebia Therapeutics in Q2 2017 and held it in 21 quarters.
  • US Bancorp's Akebia Therapeutics position peaked at $120K in Q3 2017.
  • 177 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2025.

Based on US Bancorp's 13F filing for Q3 2025, filed 12 Nov 2025.